Research
Research
The research conducted at CDD includes design, discovery and development of therapeutics for various conditions affecting human health. These diverse conditions include cancer, neurological disorders, viral diseases etc. Along with a proven track record of success in developing compounds of medicinal interest (carbovir and abacavir), CDD has added more drug candidates to its growing repertoire. Sulfanegen, an anti-cyanide prevention and treatment agent, is being developed in collaboration with Vytara Pharma Inc, a California based company. In another significant development, several cosmetic companies have shown interest in the 'CDD Functional Cosmetic' compound for the prevention and boost in activation of skin rejuvenating enzymes for people suffering from, or susceptible to, various forms of skin cancers.
-
Courtney Aldrich, PhD
Mycobacterium tuberculosis and Gram negative bacteria including Acinetobacter baumannii, Klebsiella pneumonia, and Pseudomonas aeroginosa
-
W. Thomas Shier, PhD
Carcinogenic Effects of Mycotoxins, Aflatoxins, and Fumonisins -
Robert Geraghty, PhD
HSV, cytomegalovirus, HCV, West Nile Virus, influenza A virus, HIV, coronaviruses
